First report of linezolid-resistant cfr-positive methicillin-resistant Staphylococcus aureus in humans in Portugal

Linezolid and vancomycin are the most reliable therapeutic agents to treat complicated soft tissue infections caused by multidrug-resistant methicillin-resistant Staphylococcus aureus (MRSA) strains. However, despite the fact that the prevalence of linezolid-resistant MRSA strains (LR-MRSA) remains overall low, in the past few years resistance to linezolid has been reported among human patients worldwide, imposing a public-health concern, in particular when associated with a mobile gene such as cfr [1]. The aim of this study was to identify LR-MRSA isolates recovered from infected diabetic foot ulcers and to characterise their antimicrobial resistance profiles and genetic lineage. (...)